On June 2, 2014, Omeros Corporation (NASDAQ:OMER) issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has approved Omidria (phenylephrine and ketorolac injection) 1%/0.3% for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative pain. Omidria is the first Omeros product to receive FDA approval. Omeros Corporation (NASDAQ:OMER) stock opened today at $14.44 and is currently trading at $15.11. The stock showed a positive weekly performance of 1.70%.
BioCryst Pharmaceuticals (NASDAQ:BCRX) Wells Fargo upgraded from Market Perform to Outperform with a price target of $17-$19 (from $8-$9).Analyst Brian Abrahams has a positive view on BCX-4161. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stock opened at $12.26, in current trading session and currently is at $12.39, by gaining 4.65%. The 52 week range of $1.42 – $13.33. Company’s market capitalization is 868.23 million.
Galena Biopharma, Inc. (NASDAQ:GALE) a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, announced that Mark W. Schwartz, Ph.D., Executive Vice President and Chief Operating Officer will present a corporate update at the 9th Annual JMP Securities Healthcare Conference. The presentation will take place on Wednesday, June 25, 2014 at 2:30 p.m. ET at the Westin Grand Central Hotel in New York, NY. Galena Biopharma Inc. (NASDAQ:GALE) stock is currently trading at $3.12. The EPS of the stock is -0.69. Company’s market capitalization is 368.24 million.
Gilead Sciences, Inc. (NASDAQ:GILD) on June 15 announced topline results from a Phase 3 clinical trial (GS-US-337-0113) in Japan evaluating the investigational once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg, with and without ribavirin (RBV), for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection. Gilead Sciences, Inc. (NASDAQ:GILD) stock opened the session at $81.27, and now is at $81.33. The 52 week range of the Gilead Sciences, Inc. (NASDAQ:GILD) stock remained $46.70 – $84.88 and the day range was $81.06 – $82.23.
Eli Lilly and Co (NYSE:LLY) CEO John Lechleiter has revealed in a discussion on Fox Business Network that he is anticipating more advances in the industry’s fight against cancer. Eli Lilly and Co (NYSE:LLY) stock opened today at $62.08 and is currently trading at $62.10. The stock showed a positive weekly performance of 5.31%.